Discussion about this post

User's avatar
Dr Efevretis's avatar

The strongest turn in this is moving from the single PPI to the approval framework, because that 2018 screen you cite reframes the whole question. If roughly a quarter of human-targeted drugs already inhibit a gut strain, then microbiome impact isn't a fringe effect, it's a routine one that simply wasn't being measured. The liver-kidney-heart comparison is apt: we monitor what the approval pipeline was built to see, and the microbiome sat outside that frame, so the effects only surface once millions are already taking the drug.

MitoExplorer's avatar

Dose that mean that some medications can do more harm than good ?

3 more comments...

No posts

Ready for more?